Our COVID-19 partners

IDDO works with the global, scientific community to accelerate existing knowledge through responsible data use, enabling the health, research and humanitarian communities to maximise resources, prioritise research and improve treatment outcomes.

Colorized scanning electron micrograph of an apoptotic cell (purple) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample
i
Credit: National Institute of Allergy and Infectious Diseases, NIH

CDISC

CDISC develops clinical data standards to improve the quality, documentation and integration of clinical data. The COVID-19 Interim Therapeutic Area User Guide and its associated tools were developed in partnership with IDDO.

 

COVID-19 Clinical Research Coalition

IDDO is a founding member of the COVID-19 Clinical Research Coalition formed to build collaborative solutions and accelerate urgent research on prevention and diagnosis of COVID-19 in resource-limited settings. IDDO’s Director, Professor Philippe Guérin, is a member of the COVID-19 Clinical Research Coalition steering committee.

The coalition provides free access to COVID-19 clinical trial protocols. A number of Coalition working groups are identifying and addressing the most pressing scientific and operational research questions for resource-limited settings.

 

CURE Drug Repurposing Collaboratory

IDDO is closely working with CDRC, a public-private partnership led by the Critical Path Institute in collaboration with U.S. Food and Drug Administration (FDA) and the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). CDRC builds upon the CURE ID platform for drug repurposing for infectious diseases and is a key data contributor to the COVID-19 Data Platform. Together, IDDO and CDRC are working to develop automated systems that extract critical data variables from electronic health records (EHR).

 

Drugs for Neglected Diseases initiative

IDDO is collaborating with DNDi’s response to the COVID-19 crisis. IDDO is also a partner in the ANTICOV clinical trial platform.

 

Exaptive Cognitive City

Exaptive’s Cognitive City technology delivers the COVID-19 data platform inventory and the COVID-19 living systematic review interface.

 

ISARIC

ISARIC (the International Severe Acute Respiratory and emerging Infections Consortium) is a founding partner of the COVID-19 Data Platform. Large volumes of data available on the platform have resulted from ISARIC’s collaboration of global researchers responding to COVID-19.

 

MORU Tropical Health Network

IDDO’s shares its expertise with the ongoing COPCOV trial exploring how to protect those who work in healthcare settings.

 

TDR (the Special Programme for Research and Training in Tropical Diseases)

TDR chairs the COVID-19 Data Access Committee and supports IDDO to implement training and research capacity strengthening in lower-resource settings.

 

University of Cape Town (UCT)

IDDO is working with UCT to support research to improve the treatment of COVID-19. UCT is also a member of the COVID-19 Clinical Research Coalition, and part of the working group Clinical Pharmacology & Drug Candidates which provides advice on clinical pharmacology, drug analysis, and clinical pharmacometrics relevant to COVID-19 clinical trials.

 

Vivli

IDDO has made its COVID-19 studies discoverable on the platform to boost its reach across the global research community and increase both the speed of access and re-use of data. Vivli focuses on sharing individual participant-level data from completed clinical trials to serve the international research community.


 

IDDO is also part of the World Health Organization’s GOARN network of over 250 technical institutions and networks globally that respond to acute public health events. For further information please contact us at: info@iddo.org